Towards a TDP-43-Based Biomarker for ALS and FTLD

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• TDP-43 proteinopathy is central to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
• Current ALS and FTLD diagnoses rely on clinical expertise, lacking objective biochemical markers.
• TDP-43's role in pathogenesis is established, but its detection in biofluids remains challenging.

Purpose of the Study:

• To critically review existing biofluid studies for TDP-43 in ALS and FTLD.
• To explore the potential of TDP-43 as a diagnostic biomarker for these neurodegenerative diseases.
• To identify future research directions for developing reliable TDP-43 biomarkers.

Main Methods:

• Literature review of studies measuring TDP-43 in blood and cerebrospinal fluid of ALS/FTLD patients.
• Analysis of the consistency and limitations of current TDP-43 detection methods in biofluids.
• Comparison of TDP-43 molecular pathology in brain tissue versus biofluid findings.

Main Results:

• Previous attempts to measure disease-specific TDP-43 in peripheral biofluids have yielded inconsistent results.
• Only a subset of pathological TDP-43 features observed in brain tissue has been detected in clinical biofluids.
• Significant challenges remain in reliably quantifying disease-relevant TDP-43 species in accessible biofluids.

Conclusions:

• Developing a TDP-43-based biomarker for ALS and FTLD is crucial for improving diagnosis and treatment.
• Further research is needed to overcome current inconsistencies and detect relevant TDP-43 forms in biofluids.
• Standardized methodologies are required to translate TDP-43 pathology into a viable clinical biomarker.